152 related articles for article (PubMed ID: 26069486)
21. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.
Schwendener RA; Fiebig HH; Berger MR; Berger DP
Cancer Chemother Pharmacol; 1991; 27(6):429-39. PubMed ID: 2013113
[TBL] [Abstract][Full Text] [Related]
22. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
Stover TC; Sharma A; Robertson GP; Kester M
Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model.
Alshafie GA; Abou-Issa HM; Seibert K; Harris RE
Oncol Rep; 2000; 7(6):1377-81. PubMed ID: 11032948
[TBL] [Abstract][Full Text] [Related]
24. Development of a Liposomal Formulation of Acetyltanshinone IIA for Breast Cancer Therapy.
Wang Q; Luo M; Wei N; Chang A; Luo KQ
Mol Pharm; 2019 Sep; 16(9):3873-3886. PubMed ID: 31389706
[TBL] [Abstract][Full Text] [Related]
25. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
[TBL] [Abstract][Full Text] [Related]
26. Preparation and evaluation of lipid vesicles of camptothecin as targeted drug delivery system.
Prabhakara P; Zenia T; Marina K; Shama KP; Girish SN; Matapady NH
Pak J Pharm Sci; 2013 Jul; 26(4):779-86. PubMed ID: 23811458
[TBL] [Abstract][Full Text] [Related]
27. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
28. A novel 5-Fluorouracil targeted delivery to colon cancer using folic acid conjugated liposomes.
Handali S; Moghimipour E; Rezaei M; Ramezani Z; Kouchak M; Amini M; Angali KA; Saremy S; Dorkoosh FA
Biomed Pharmacother; 2018 Dec; 108():1259-1273. PubMed ID: 30372827
[TBL] [Abstract][Full Text] [Related]
29. Drug-fortified liposomes as carriers for sustained release of NSAIDs: The concept and its validation in the animal model for the treatment of arthritis.
Pawar VA; Manjappa AS; Murumkar PR; Gajaria TK; Devkar RV; Mishra AK; Yadav MR
Eur J Pharm Sci; 2018 Dec; 125():11-22. PubMed ID: 30219410
[TBL] [Abstract][Full Text] [Related]
30. Celecoxib-Loaded Cubosomal Nanoparticles as a Therapeutic Approach for
Alshawwa SZ; El-Masry TA; Nasr M; Kira AY; Alotaibi HF; Sallam AS; Elekhnawy E
Microorganisms; 2023 Sep; 11(9):. PubMed ID: 37764091
[TBL] [Abstract][Full Text] [Related]
31. Liposomal Entrapment of 4-Nerolidylcatechol: Impact on Phospholipid Dynamics, Drug Stability and Bioactivity.
Gaetil MP; Benfica PL; Mendes LP; Vieira MS; Anjos JL; Alonso A; Rezende KR; Valadares MC; Lima EM
J Nanosci Nanotechnol; 2015 Jan; 15(1):838-47. PubMed ID: 26328448
[TBL] [Abstract][Full Text] [Related]
32. Metformin-Encapsulated Liposome Delivery System: An Effective Treatment Approach against Breast Cancer.
Shukla SK; Kulkarni NS; Chan A; Parvathaneni V; Farrales P; Muth A; Gupta V
Pharmaceutics; 2019 Oct; 11(11):. PubMed ID: 31661947
[TBL] [Abstract][Full Text] [Related]
33. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
[TBL] [Abstract][Full Text] [Related]
34. [Chemopreventive effect of tamoxifen combined with celecoxib on DMBA-induced breast cancer in rats].
Kang HF; Wang XJ; Liu XX; Dai ZJ; Xue FJ; Xue XH
Ai Zheng; 2006 Nov; 25(11):1346-50. PubMed ID: 17094899
[TBL] [Abstract][Full Text] [Related]
35. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Krishna R; Mayer LD
Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
[TBL] [Abstract][Full Text] [Related]
36. Potential antioxidant activity of celecoxib and amtolmetin guacyl: in vitro studies.
Kirkova M; Alexandova A; Kesiova M; Tsvetanova E; Georgieva A; Todorov S
Auton Autacoid Pharmacol; 2007 Jan; 27(1):13-8. PubMed ID: 17199871
[TBL] [Abstract][Full Text] [Related]
37. A parenteral econazole formulation using a novel micelle-to-liposome transfer method: in vitro characterization and tumor growth delay in a breast cancer xenograft model.
Cogswell S; Berger S; Waterhouse D; Bally MB; Wasan EK
Pharm Res; 2006 Nov; 23(11):2575-85. PubMed ID: 17086505
[TBL] [Abstract][Full Text] [Related]
38. Liposomal formulations of carboplatin injected by convection-enhanced delivery increases the median survival time of F98 glioma bearing rats.
Shi M; Anantha M; Wehbe M; Bally MB; Fortin D; Roy LO; Charest G; Richer M; Paquette B; Sanche L
J Nanobiotechnology; 2018 Oct; 16(1):77. PubMed ID: 30290821
[TBL] [Abstract][Full Text] [Related]
39. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models.
Yuan ZP; Chen LJ; Fan LY; Tang MH; Yang GL; Yang HS; Du XB; Wang GQ; Yao WX; Zhao QM; Ye B; Wang R; Diao P; Zhang W; Wu HB; Zhao X; Wei YQ
Clin Cancer Res; 2006 May; 12(10):3193-9. PubMed ID: 16707620
[TBL] [Abstract][Full Text] [Related]
40. A study on the role of (+)-catechin in suppression of HepG2 proliferation via caspase dependent pathway and enhancement of its in vitro and in vivo cytotoxic potential through liposomal formulation.
Jain P; Kumar N; Josyula VR; Jagani HV; Udupa N; Mallikarjuna Rao C; Vasanth Raj P
Eur J Pharm Sci; 2013 Nov; 50(3-4):353-65. PubMed ID: 23954456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
